2-Year outcomes of dolutegravir plus lamivudine in ART-naive and pre-treated people living with HIV in Germany: Real-world Data From the URBAN Cohort

被引：0
|
作者：
Beer, Daniel [1 ]
Scherzer, Jenny [2 ]
Noe, Sebastian [3 ]
Scholten, Stefan [4 ]
Wyen, Christoph [5 ]
Postel, Nils [6 ]
Degen, Olaf [7 ]
Sabranski, Michael [8 ]
Westermayer, Bernd [9 ]
Dymek, Kathrin M. [2 ]
Baum, Alexander [2 ]
机构：
[1] IPZB Aachen Praxis Dr H Knechten, Aachen, Germany
[2] ViiV Healthcare, Munich, Germany
[3] MVZ Munchen Goethepl, Munich, Germany
[4] Praxis Hohenstaufenring, Cologne, Germany
[5] Praxis Ebertpl, Cologne, Germany
[6] Prinzmed, Munich, Germany
[7] Univ Klinikum Hamburg Eppendorf, Hamburg, Germany
[8] ICH Study Ctr, Hamburg, Germany
[9] GSK, Munich, Germany
来源：
HIV MEDICINE | 2023年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
81003
引用
收藏
页码：28 / 30
页数：3
相关论文
共 39 条
  • [31] CARAVEL: Evaluation of real-world antiviral effectiveness and sustainability of the 2-drug regimen Dolutegravir/Lamivudine fixed dose combination (FDC) in treatment-naive adults and pre-treated adults who are virologicaly suppressed, in routine clinical care, in France. One-year interim analysis results
    Philibert, P.
    Charpentier, C.
    Naguleswaran, N.
    Philippe, C.
    Roustand, L.
    Vouillot, C.
    Hocqueloux, L.
    HIV MEDICINE, 2023, 24 : 71 - 72
  • [32] Real-world effectiveness of Dolutegravir plus Lamivudine (DTG+3TC) in treatment-naive people with HIV-1 (PWH) and low CD4+cell count or high viral load at baseline: A systematic literature review
    Letang, E.
    Barber, T. J.
    Allavena, C.
    Hocqueloux, L.
    Casado, J.
    Di Giambenedetto, S.
    Cabello-Ubeda, A.
    Monforte, A. d'Arminio
    Kabra, M.
    Priest, J.
    Milinkovic, A.
    Jones, B.
    HIV MEDICINE, 2023, 24 : 144 - 145
  • [33] Efficacy of dolutegravir plus lamivudine in treatment-naive people living with HIV without baseline drug-resistance testing available: 48-week results from the randomized D2ARLING study
    Cordova, Ezequiel
    Hernandez Rendon, Jeniffer
    Mingrone, Veronica
    Martin, Patricio
    Arevalo Calderon, Gisela
    Seleme, Soledad
    Ballivian, Jamile
    Porteiro, Norma
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 52 - 52
  • [34] Patient-reported outcomes among people living with HIV on bictegravir/ emtricitabine/tenofovir alafenamide fixed-dose combination: Real-world data from Latin America
    Cecchini, D. M.
    Seleme, S.
    Mingrone, M. V.
    Diana Menendez, S.
    Mauas, R.
    Bottaro, E.
    Cassetti, I.
    HIV MEDICINE, 2023, 24 : 414 - 414
  • [35] Treatment Experienced People Living With HIV switching to DOR/3TC/TDF in Outpatient Setting: Real-World Data on Tolerability and Cost Savings From an Italian Multicenter Cohort
    Iannone, Valentina
    Ciccullo, Arturo
    Moschese, Davide
    Giacomelli, Andrea
    Fabbiani, Massimiliano
    Lagi, Filippo
    Papalini, Chiara
    De Vito, Andrea
    Cossu, Maria Vittoria
    Di Giambenedetto, Simona
    Borghetti, Alberto
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2024, 96 (02) : e10 - e11
  • [36] Predictors for choosing doravirine-based versus INSTI-based regimen in ART-naïve and ART-experienced people with HIV in real-world setting: Data from the Icona cohort
    d'Arminio Monforte, Antonella
    Tavelli, Alessandro
    Quiros-Roldan, Eugenia
    Fabbiani, Massimiliano
    Ferrara, Micol
    Lo Caputo, Sergio
    Squillace, Nicola
    Rusconi, Stefano
    Ponzano, Marta
    Bovis, Francesca
    Antinori, Andrea
    Saracino, Annalisa
    Cozzi-Lepri, Alessandro
    HIV MEDICINE, 2024,
  • [37] Evaluation of changes in Systematic Coronary Risk Evaluation 2 (SCORE2) in experienced people with HIV switching to DOR/3TC/TDF: real-world data from DOROTEA multicentre cohort
    Iannone, Valentina
    Borghetti, Alberto
    Giacomelli, Andrea
    Moschese, Davide
    Lagi, Filippo
    Fabbiani, Massimiliano
    Rabbione, Andrea
    Formica, Giuseppe
    Lombardi, Francesca
    Papalini, Chiara
    Tommasi, Andrea
    Francisci, Daniela
    De Vito, Andrea
    Madeddu, Giordano
    Cossu, Maria Vittoria
    Di Giambenedetto, Simona
    Ciccullo, Arturo
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 254 - 255
  • [38] The impact of TP53 mutations on EGFR mt plus NSCLC IV patients treated with 3rd generation TKI on 2nd line or further line therapy: Real-world data from two certified lung cancer centers in Germany
    Roeper, J.
    Christopoulos, P.
    Falk, M.
    Heukamp, L. C.
    Stenzinger, A.
    Thomas, M.
    Griesinger, F.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S772 - S773
  • [39] Abatacept retention and clinical outcomes in Austrian patients with rheumatoid arthritis: real-world data from the 2-year ACTION studyAbatacepttherapietreue und klinische Ergebnisse bei Patienten mit rheumatoider Arthritis in Österreich: 2-Jahres-Daten der ACTION-Studie aus dem Praxisalltag
    Peter Peichl
    Rieke Alten
    Mauro Galeazzi
    Hanns-Martin Lorenz
    Hubert Nüßlein
    Federico Navarro
    Yedid Elbez
    Melanie Chartier
    Roland Hackl
    Christiane Rauch
    Sean E Connolly
    Wiener Medizinische Wochenschrift, 2020, 170 : 132 - 140
1234